RATIONALE: Eosinophilic esophagitis (EoE) is an increasing, allergic disease with variable symptoms that progress with age. While adult predominant studies have shown symptoms differ significantly in male and female patients, no pediatric studies have been performed. We compared clinical features by sex in a pediatric EoE cohort. METHODS: At endoscopy, 98 EoE patients were recruited for a cross sectional study. Participants completed demographic and clinical questionnaires and medical records were reviewed for esophageal biopsy results. RESULTS: In the whole cohort, ages ranged from 2 to 19 (median 12) and 89% were white. There were 39 female and 59 male patients, and there were no significant sex-related differences in race, body mass index (BMI), concurrent allergic diseases, peak esophageal eosinophil counts, or symptoms. For further analysis, patients were divided into four groups based on sex and age: i) males<13, ii) males> _13, iii) females<13, and iv) females> _13. Prevalence of reported food allergies was higher in male patients<13 (65%, p50.005). Peak eosinophil counts were higher in males> _13 compared with females> _13 [median 63 eosinophils/high power field (eos/hpf) and 44 eos/hpf respectively, p50.045]. Females> _13 were more likely to have abdominal pain (68%, p50.01), and males> _13 were more likely to report food impactions (78%, p50.005). BMI was lowest in females<13 and highest in females>13 (p<0.001). Histologic remission was significantly less frequent in males<13 (31%) compared with females<13 (69%) (p50.043). CONCLUSIONS: There were age-related sex differences in symptoms, markers of allergy, and outcomes in pediatric EoE patients. These group differences appear to result from separate changes in both sexes after adolescence.
University of Virginia, Charlottesville, VA. RATIONALE: Eosinophilic esophagitis (EoE) is an increasing, allergic disease with variable symptoms that progress with age. While adult predominant studies have shown symptoms differ significantly in male and female patients, no pediatric studies have been performed. We compared clinical features by sex in a pediatric EoE cohort. METHODS: At endoscopy, 98 EoE patients were recruited for a cross sectional study. Participants completed demographic and clinical questionnaires and medical records were reviewed for esophageal biopsy results. RESULTS: In the whole cohort, ages ranged from 2 to 19 (median 12) and 89% were white. There were 39 female and 59 male patients, and there were no significant sex-related differences in race, body mass index (BMI), concurrent allergic diseases, peak esophageal eosinophil counts, or symptoms. For further analysis, patients were divided into four groups based on sex and age: i) males<13, ii) males> _13, iii) females<13, and iv) females> _13. Prevalence of reported food allergies was higher in male patients<13 (65%, p50.005). Peak eosinophil counts were higher in males> _13 compared with females> _13 [median 63 eosinophils/high power field (eos/hpf) and 44 eos/hpf respectively, p50.045]. Females> _13 were more likely to have abdominal pain (68%, p50.01), and males> _13 were more likely to report food impactions (78%, p50.005). BMI was lowest in females<13 and highest in females>13 (p<0.001). Histologic remission was significantly less frequent in males<13 (31%) compared with females<13 (69%) (p50.043). CONCLUSIONS: There were age-related sex differences in symptoms, markers of allergy, and outcomes in pediatric EoE patients. These group differences appear to result from separate changes in both sexes after adolescence. University of Virginia, Charlottesville, VA. RATIONALE: During milk oral immunotherapy (OIT), IgG4 levels to cow's milk (CM) increase and may have a protective effect on IgEmediated responses. On the other hand, elevated levels of milk-specific IgG4 might be related to eosinophilic esophagitis (EoE). METHODS: We evaluated milk allergic patients during milk OIT (baseline and end of treatment) with specific IgE and IgG4 to milk, alactalbumin, b-lactoglobulin, caseins and wheat using commercially available ImmunoCAP. All patients had endoscopy prior to treatment. RESULTS: Of 6 patients evaluated, 1 developed symptoms suggestive of EoE and the diagnosis was confirmed on follow-up biopsy. Of the 5 patients without EoE, baseline IgE to milk was 34-671 kUA/L. During OIT, IgG4 to a-lactalbumin increased 0-59 fold (pre:0-3mg/mL; end:0-172mg/ mL), b-lactoglobulin increased 11-310 fold (pre:0.4-2mg/mL; end:6.3-294mg/mL), casein increased 3-19 fold (pre:0.5-24mg/mL; end:2.5-102mg/mL) and wheat increased 0.6-3 fold (pre:1.73-6.15mg/mL; end:3.7-13.6mg/mL). The subject who developed EoE had a baselineIgE to milk of 340 kUA/L andIgG4 to a-lactalbumin increased 107 fold (pre:0.5mg/mL; end:53.5mg/mL), b-lactoglobulin increased 177 fold (pre:0.37mg/mL; end:65.7mg/mL), casein increased 34 fold (pre:5.33 mg/mL; end: 182 mg/mL) and wheat increased 2 fold (pre:1.82mg/mL; end:4.1mg/mL). CONCLUSIONS: EoE is highly associated with IgE-mediated food allergy and can result from OIT. In this case series 1 of 6 subjects developed EoE during milk OIT. Although levels of sIgG4 to CM proteins were high and increased with OIT, these values did not distinguish the subject who developed EoE from other subjects who received OIT. ) and pulmonary specialists (2.5%). Before diagnosis, 29.6% of patients underwent upper gastrointestinal endoscopy, 11.8% had allergy testing and 7.5% had esophageal dilation. Overall, 30% of patients had > _1 emergency room (ER) visit; these were most commonly associated with food impaction. Six percent had > _1 inpatient admission -foreign body in the esophagus was the most common primary diagnosis. The most common outpatient specialist visits on the EoE diagnosis date were visits to gastroenterologists (30.3% of patients), allergists (7.7%) and pediatric gastroenterologists (6.1%). Over 50% of patients (n512,098; 52.6%) had an upper gastrointestinal endoscopy on the diagnosis date. CONCLUSIONS: High numbers of outpatient visits, clinical diagnostics, and ER/in-patient admissions in the 12 months prior to and at diagnosis indicate that a large clinical and healthcare utilization burden exists in the patient evaluation for the diagnosis of EoE in the USA.
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